Angioscopic evaluation of site-specific administration of ReoPro

Catheterization and Cardiovascular Diagnosis

Volumn 42, Issue 2, 1997, Pages 181-184

  Bailey, Steven R ^a,b   O'Leary, Edward ^a   Chilton, Robert ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Cardiac Catheterization Laboratories   (United States)

Author keywords

Angioscope; Local delivery; Thrombus

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CONTRAST MEDIUM; HEPARIN;

ANGIOSCOPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; REVIEW; THROMBOCYTE; THROMBUS;

EID: 0030830096     PISSN: 00986569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R     Document Type: Review

References (9)

1. de Feyter PJ, van den Brand M, Jaarman G, van Domburg R, Serruys PW, Suryapranata H: Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty: Frequency, prediction, clinical course, management and follow-up. Circulation 83:927-936, 1991.
2. Ellis SG, Vandormeael MG, Cowley MJ, DiSciascio G, Delingonul U, Topol EJ, Bulle TM, and the Multivessel Angioplasty Prognosis Group: Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 82:1193-1202, 1990.
3. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of The EPIC Investigators: Randomized trial of coronary intervention with antibody against platelet Hb/IIIa integrin for reduction in clinical restenosis: results at six months. Lancet 343:881-886, 1994.
4. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ for the EPIC investigators: Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. J Am Coll Cardiol 28:849-855, 1996.
5. The EPIC Investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994.
6. Mitchel JF, Azrin MA, Fram DB, Hong MK, Wong SC, Barry JJ, Bow LM, Curley TM, Kiernan FJ, Waters DD, Leon MB, McKay RG: Inhibition of platelet deposition and lysis of coronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 90:1979-1988, 1994.
7. Camezind E, Kint PP, Dimario C, Lithgart J, Van der Giessen W, Boersma F, Serruys PW: Local intracoronary heparin delivery in man: Acute feasibility and long-term results. Circulation 92:2463-2472, 1995.
8. Mitchel, JF, Azrin MA, Alberghini TV, Fusco M, Kiernan FJ, Waters DW, McKay RG: Local delivery of ReoPro: Pharmacokinetics and effect on platelet deposition following balloon angioplasty. Circulation 94:1-615, 1996 (abst).
9. White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Sahw D, Jain SP, Bass TA, Heuser RR, Tierstein PS, Bonan R, Walter PD, Smalling RW: Coronary thrombi increase PTCA risk: Angioscopy as a clinical tool. Circulation 93:253-258, 1996.